ENGNW enGene Therapeutics Inc. - Warrants

0.2201USD-11.92%Mkt Cap: —P/E: —9d ago

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead…

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-117.30M USD

Revenue/Share—

Last Price0.2201 USD

Fiscal Year End—

MR Quarter—

Employees81

CountryUS

SectorHealthcare

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.05

EPS (TTM)—

EPS (Forward)—

52W Range

0.18012% of range2.230

52W High2.230 USD

52W Low0.1801 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-69.94%

ROA-52.97%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-99.24M USD

CapEx (TTM)1.49M USD

FCF Margin—

FCF Yield—

Net Debt-233.05M USD

Net Debt/EBITDA1.71

Balance Sheet

Debt/Equity0.19

Current Ratio10.21

Quick Ratio9.89

Book Value/Sh3.44 USD

Cash/Share3.97 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float32.75M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta-0.28

S&P 52W Chg15.78%

Avg Vol (30d)13.45K

Avg Vol (10d)—

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—

ENGNW enGene Therapeutics Inc. - Warrants

Industry Peers

Key Statistics